Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) hired its associate Kelun Jiaxun for auxiliary promotional services of its drug SKB264, according to a Hong Kong bourse filing Tuesday.
Shares of the drug maker fell nearly 2% in morning trade Wednesday.
The framework will last till the end of 2028, with annual caps of 20 million yuan in service fees payable by Sichuan Kelun-Biotech to Kelun Jiaxun.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.